150 related articles for article (PubMed ID: 19686788)
1. Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine.
Tiwari S; Goyal AK; Mishra N; Khatri K; Vaidya B; Mehta A; Wu Y; Vyas SP
J Control Release; 2009 Dec; 140(2):157-65. PubMed ID: 19686788
[TBL] [Abstract][Full Text] [Related]
2. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
[TBL] [Abstract][Full Text] [Related]
3. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
[TBL] [Abstract][Full Text] [Related]
4. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N
Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140
[TBL] [Abstract][Full Text] [Related]
5. Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose.
Huang WC; Deng B; Mabrouk MT; Seffouh A; Ortega J; Long C; Miura K; Wu Y; Lovell JF
Malar J; 2020 Aug; 19(1):309. PubMed ID: 32859199
[TBL] [Abstract][Full Text] [Related]
6. Poor CD4
Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S
Front Immunol; 2021; 12():732667. PubMed ID: 34659219
[No Abstract] [Full Text] [Related]
7. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
[TBL] [Abstract][Full Text] [Related]
8. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N
Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750
[TBL] [Abstract][Full Text] [Related]
9. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.
LeBlanc R; Vasquez Y; Hannaman D; Kumar N
Vaccine; 2008 Jan; 26(2):185-92. PubMed ID: 18054817
[TBL] [Abstract][Full Text] [Related]
10. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
[TBL] [Abstract][Full Text] [Related]
12. A malaria vaccine adjuvant based on recombinant antigen binding to liposomes.
Huang WC; Deng B; Lin C; Carter KA; Geng J; Razi A; He X; Chitgupi U; Federizon J; Sun B; Long CA; Ortega J; Dutta S; King CR; Miura K; Lee SM; Lovell JF
Nat Nanotechnol; 2018 Dec; 13(12):1174-1181. PubMed ID: 30297818
[TBL] [Abstract][Full Text] [Related]
13. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
[TBL] [Abstract][Full Text] [Related]
14. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen.
Mlambo G; Kumar N; Yoshida S
Vaccine; 2010 Oct; 28(43):7025-9. PubMed ID: 20709008
[TBL] [Abstract][Full Text] [Related]
15. Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.
Pirahmadi S; Zakeri S; Mehrizi AA; Djadid ND; Raz AA; Sani JJ
Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936155
[No Abstract] [Full Text] [Related]
16. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
[TBL] [Abstract][Full Text] [Related]
18. Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.
Zhu D; Wu Y; McClellan H; Dai W; Rausch K; Jones D; Aebig J; Barnafo E; Butler B; Lambert L; Narum DL; Duffy PE
Vaccine; 2017 May; 35(24):3232-3238. PubMed ID: 28479180
[TBL] [Abstract][Full Text] [Related]
19. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles.
Kumar R; Ledet G; Graves R; Datta D; Robinson S; Bansal GP; Mandal T; Kumar N
Pharm Res; 2015 Dec; 32(12):3827-36. PubMed ID: 26113235
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial.
de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S
Front Immunol; 2021; 12():694759. PubMed ID: 34335606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
